A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
VIVOS INC Precision Radionuclide Therapy™ (PRnT™)
Vivos Inc. is a medical device company with its patented Precision Radionuclide Therapy™.
Vivos Inc.
The Next Generation Cancer Treatment
RadioGel® for Human Cancer
RadioGel® is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT™). RadioGel® is a hydrogel liquid containing yttrium-90 phosphate micro-particles that may be administered directly into a tumor
Precision Radionuclide Therapy™ (PRnT™)
Our patented Precision Radionuclide Therapy™ (PRnT™) is the future of radionuclide cancer treatment – the insertion of our radionuclide device directly into the tumor tissue.
IsoPet® for Animal Cancer
IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT™). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.
Press Releases
IDE Submission
Press Releases - Vivos Inc.
GlobeNewsWire has a list of all press releases and is the only place for the most accurate and up to date information on our revolutionary cancer treatment - Precision Radionuclide Therapy™ (PRnT™)
IDE Submission
IDE Submission
IDE Submission
IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the RadioGel® Precision Radionuclide Therapy.
Research Papers
IDE Submission
IDE Submission
Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite
Published online 2020 Feb 5
Darrell R. Fisher,1 Janean Fidel,2 and Charles A. Maitz3
Investor Relations
We are trading under the OTCQB: RDGL and value our very loyal shareholders and followers and strive to have the most accurate and up to date information on our stock information.
SEC Filings
We are pleased to provide the following the most up to date SEC filings through www.sec.gov
Vivos Inc. Articles
Vivos Inc. Articles
We are pleased to provide you with our Quarterly Reports